Zurück
  • Abstractvortrag
  • VS-13-4

A Randomised Open-Label Trial of Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19 as model of early treatment in a pandemia with a new pathogen: Experience from collection of very high-titer plasma from superimmunized individuals

Termin

Datum:
Zeit:
Redezeit:
Diskussionszeit:
Ort / Stream:
Gustav Mahler 3.1

Session

COVID-19

Themen

  • 1. Blutspende und Donormanagement
  • 19. COVID-19

Mitwirkende

Prof. Dr. med. Bernd Jahrsdörfer (Ulm / DE), Simone Hoffmann (Ulm / DE), Dr. Matthias Johnsen (Dresden / DE), Dr. med Thomas Burkhardt (Plauen / DE), Dr. med Youhai Li (Ulm / DE), Dr. med. Henrike Hofmann (Ulm / DE), Carolin Ludwig (Ulm / DE), Christiane Vieweg (Ulm / DE), Christina Krämer (Ulm / DE), Dr. Rebecca Müller (Mannheim / DE), Dr. Thomas Appl (Ulm / DE), Prof. Erhard Seifried (Frankfurt a. M. / DE), Dr. med. Sixten Körper (Ulm / DE), Prof. Hubert Schrezenmeier (Ulm / DE)

  • © Conventus Congressmanagement & Marketing GmbH